Previous Article | Next Article ![]()
Journal of Bacteriology, February 2005, p. 1219-1226, Vol. 187, No. 4
0021-9193/05/$08.00+0 doi:10.1128/JB.187.4.1219-1226.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, Cornell University, Ithaca, New York
Received 13 September 2004/ Accepted 8 November 2004
|
|
|---|
|
|
|---|
Although a large number of putative LuxR family members have been identified, only a few of them have been extensively studied genetically, biochemically, and structurally. When overexpressed in Escherichia coli, several LuxR-type proteins accumulate only in an insoluble form in the absence of their cognate autoinducers but are highly soluble in their presence. These proteins include LuxR from V. fischeri (32), TraR from Agrobacterium tumefaciens (42), and CepR from Burkholderia cenocepacia (34). These data suggest that these proteins require AHLs for proper folding into a native conformation. In the case of TraR, AHLs were further shown to be required for cotranslational folding of the nascent protein into a protease-resistant conformation (43). This indicates that AHLs may function for this and related proteins as scaffolds for correct protein folding. In three studies, a highly restricted set of AHLs acted as agonists for a particular LuxR-type protein, and in two of these studies, several heterologous AHLs acted as rather potent antagonists (28, 34, 40).
The TraR protein of A. tumefaciens is one of the best studied members of the LuxR family. TraR requires its cognate AHL, 3-oxooctanoyl-homoserine lactone (OOHL), for folding, for protease resistance, and for dimerization. In the absence of OOHL, the nascent TraR protein is rapidly destroyed by proteolysis in A. tumefaciens and in E. coli (42, 43). When TraR was expressed at native levels, it was easily detected by Western immunoblotting when OOHL was added but was undetectable in the absence of OOHL due to rapid proteolysis (3). This is further supported by the X-ray crystal structures of TraR-OOHL-DNA complexes, in which OOHL is buried deeply within the hydrophobic core of the protein and has no significant contact with the aqueous environment outside the protein (33, 39). Genetic, biochemical, and structural studies of several LuxR-type proteins indicate that a number of conserved residues in the N-terminal domain are important for AHL binding and that mutation of these residues often causes dramatically impaired AHL binding (3, 16, 18). TraR binds OOHL virtually irreversibly under native conditions, though it can be slowly released by using large amounts of nonionic detergents (43).
Given our previous data showing that wild-type TraR requires OOHL for correct folding and protease resistance, it seemed worthwhile to try to isolate mutant alleles of traR that activate a target promoter in the absence of OOHL. We know of only one LuxR-type protein, LuxR itself, in which such constitutive mutations have been found. In two studies, a total of eight point mutations showed an elevated level of activity in the absence of autoinducer (25, 31). Surprisingly, these mutant genes encode sequences spanning the length of the LuxR protein including the C-terminal DNA binding domain. In addition, deletion mutations of LuxR and of the Pseudomonas aeruginosa LasR protein that remove the entire N-terminal domain also result in constitutive activity (6, 16). In the case of LuxR, it was proposed that the N-terminal domain inhibits the C-terminal domain, that autoinducer neutralizes this inhibition in the wild-type protein, and that inhibition can be relieved either by removing the N-terminal domain or by point mutations that block transduction of this inhibitory signal. However, several genetic, biochemical, and structural studies indicate that the N-terminal domains of LuxR and TraR play a positive role in protein function, both by mediating dimerization and by contacting RNA polymerase (4, 7, 18, 41). This complicates the interpretation of these data and underscores the need to isolate and study constitutive alleles encoding TraR, a protein that has been exceptionally amenable to biochemical analysis.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Strains and plasmids used in this study
|
by transformation, and selecting for Spr. To ensure that these plasmids contained mutant traR alleles, they were retransformed into KYC55(pJZ372) and screened for TraR activity with X-Gal. Plasmids containing mutant traR alleles were analyzed by agarose gel electrophoresis and by automated DNA sequencing. For plasmid mutagenesis, pJZ335 was introduced into E. coli XL-1 Red competent cells (Stratagene) by transformation. Ten transformants were inoculated individually into LB broth supplemented with 100 µg of spectinomycin ml1 and cultured at 37°C with vigorous shaking. Cultures were diluted 1,000-fold into fresh LB broth every 10 generations. Plasmid DNA was prepared from the cultures after 20 and 40 generations, using a Qiaquick Spin column (QIAGEN), and were introduced into KYC55(pJZ372) by electroporation. Cells were plated on AT minimal agar plates containing 0.5% glucose, appropriate antibiotics, IPTG, and X-Gal and were incubated at 28°C. Blue colonies were analyzed as described above.
Assays of TraR-dependent activities in vivo. Bioassays for TraR activity were conducted with derivatives of A. tumefaciens strain KYC55(pJZ372) containing a second plasmid expressing either wild-type TraR or a TraR variant. These strains were cultured in AT minimal medium supplemented with 500 µM IPTG and 250 nM OOHL, grown with vigorous aeration for 12 h at 28°C, and assayed for ß-galactosidase activity (20). All data represent the averages of two independent experiments, and error bars represent standard deviations.
Immunological assays of TraR accumulation in vivo. A. tumefaciens strain KYC55(pJZ372) containing a second plasmid expressing either wild-type TraR or a TraR variant was cultured at 28°C in AT minimal medium supplemented with antibiotics, 500 µM IPTG, and 250 nM OOHL. Cells were harvested at late exponential growth phase, resuspended in 1 ml of TEDG buffer (4), and disrupted with a French pressure minicell (10,000 lb/in2). The resulting lysates were separated into soluble and pellet fractions by ultracentrifugation (65,000 x g for 30 min) and were size fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred by electrophoresis to a nitrocellulose membrane (Bio-Rad) and were immunodetected with affinity-purified polyclonal anti-TraR rabbit antiserum as described previously (3).
Immunoprecipitation assays of pulse-labeled TraR. A. tumefaciens strains expressing TraR were cultured at 28°C in AT minimal medium supplemented with appropriate antibiotics and 500 µM IPTG until exponential growth phase. [S35]methionine was added to the cultures to a final concentration of 5 µCi ml1, and after an interval of 5 min, nonlabeled methionine was added to the cultures at a final concentration of 2 mM. Cells were withdrawn at various intervals, washed with cold Slota buffer (3), and immediately frozen at 80°C. Cell pellets were resuspended in 450 µl of an ice-cold lysis buffer (50 mM Tris-HCl [pH 7.9], 200 mM NaCl, 10 mM EDTA, 1 mM dithiothreitol, 1 mM ß-mercaptoethanol, 0.1% protease inhibitor cocktails, 1% NP-40, 500 µg of freshly prepared lysozyme ml1) and were incubated on ice for 30 min. The resulting lysates were ultracentrifuged and were subjected to immunoprecipitation by using prepurified TraR antibody and protein A-agarose following a published protocol (15). Results were analyzed by using a Storm B840 PhosphorImager (Molecular Dynamics).
Screening of TraR random fusions.
Plasmid pYC336 was constructed by cloning a traR fragment lacking its start codon from pJZ301 (4) between the BamHI and HindIII sites of pPZP201 (13). Chromosomal DNA of E. coli DH5
was prepared as described previously (11). Chromosomal DNA and pYC336 were subjected to restriction enzyme digestions, purified by using Qiaquick PCR purification kits (QIAGEN), and ligated overnight at 16°C. Ligated DNA was introduced into strain KYC55(pJZ372) by electroporation. Cells were plated on AT minimal agar plates with appropriate antibiotics, 500 µM IPTG, and 40 µg of X-Gal ml1 and were incubated at 28°C. Blue colonies were analyzed by methods described above.
Protein overexpression and gel mobility shift assays.
Strains DH5
(pE3A7) and DH5
(pJZ335) were cultured in 100 ml of LB medium containing 100 µg of spectinomycin ml1 and 500 µM IPTG in the presence or absence of OOHL at 37°C. Cells were harvested at exponential growth phase, resuspended in 2 ml of TEDG buffer, and disrupted with a French pressure minicell (10,000 lb/in2). Cell debris was removed by ultracentrifugation (65,000 x g for 30 min), and cleared lysates were diluted and used for gel mobility shift assays. A 240-bp fragment containing the traA-traC intergenic region was cut from pJZ304 by digestion with XbaI and HindIII and was end labeled by using [
-32P]dATP and the Klenow fragment (3'
5' exo) of DNA polymerase I. Binding reaction mixtures containing 1012 M DNA and cleared lysates in the amounts indicated were used at 4°C in a buffer containing 10 mM Tris-HCl (pH 7.9), 1 mM EDTA, 1 mM dithiothreitol, 30 µg of calf thymus DNA ml1, 20 µg of bovine serum albumin ml1, and 10% glycerol. Samples were incubated for 20 min and size fractionated at 4°C, using 5% polyacrylamide gels in 0.5x TBE buffer (42). Gels were analyzed with a Storm PhosphorImager.
|
|
|---|
![]() View larger version (34K): [in a new window] |
FIG. 1. Construction of the strains used for whole-cell mutagenesis and plasmid mutagenesis. (A) Three plasmids were introduced into strain KYC55, which lacks a Ti plasmid. Plasmid pJZ335 contains a Plac-traR fusion for TraR expression; plasmid pJZ372 contains a PtraI-lacZ fusion for screening of expression of the PtraI promoter; plasmid pJZ407 contains a PtraI-ocd fusion for selection of PtraI expression. (B) pJZ335 was mutagenized by continued growth in strain XL1-Red and then introduced into KYC55(pJZ372) by electroporation. Up-regulation of the PtraI promoter was screened by using X-Gal minimal medium.
|
Characterization of two constitutive mutants of TraR. Twelve constitutive candidate mutants were identified as a result of the whole-cell mutagenesis described above, while no mutants were found by plasmid mutagenesis. Of the 12 candidates, 10 were found to have wild-type traR genes (data not shown), suggesting that these strains had cis-acting mutations in the reporter fusions. The two remaining candidates showed TraR-dependent elevated activity of the traI-lacZ reporter. We recovered pJZ335 plasmid derivatives (designated pYCM101 and pYCM110) from those two strains. We introduced these plasmids into strain KYC55(pJZ372) by transformation, cultured the resulting strains in the presence or absence of OOHL and IPTG, and measured ß-galactosidase specific activity. Plasmids pYCM101 and pYCM110 activated the traI-lacZ fusion at 30 and 110 Miller units, respectively (Fig. 2A), a much higher level than that observed for TraR from the wild-type pJZ335 (less than 2 Miller units). In the presence of OOHL, they activated the lacZ reporter slightly more strongly than did the wild type. Unlike activity from the wild-type strain, ß-galactosidase activity from strains containing pYCM101 or pYCM110 was not significantly enhanced by IPTG (Fig. 2A).
![]() View larger version (23K): [in a new window] |
FIG. 2. (A) Assays of ß-galactosidase specific activities of derivatives of KYC55(pJZ372) containing the wild-type plasmid pJZ335, pYCM101, or pYCM110 in the presence or absence of 250 nM OOHL and 500 µM IPTG. (B) traR fusions found in pYCM101 and pYCM110 and the wild-type traR in the parent plasmid pJZ335. (C) Alignment of the first 20 residues of the amino termini of AAC in pJZ407 and DHFR from S. enterica.
|
apo-AAC-TraR and apo-TraR produced from pYCM101 accumulated in vivo due to reduced protein turnover. In the absence of OOHL, TraR is rapidly destroyed by proteolysis in both E. coli and A. tumefaciens (42, 43) and did not accumulate to significant levels when mildly overproduced in strain KYC55(pJZ335) (3). We reasoned that the constitutive activities of the two mutants might be attributable to their proteolytic stability. Using the candidate with the stronger activity (pYCM101), we performed Western immunoblot assays to compare the production and stability of the AAC-TraR fusion protein with that of wild-type TraR. We found two major protein bands, one corresponding in size to native TraR and the other corresponding in size to the AAC-TraR fusion protein (Fig. 3A, lanes 5 to 8). Approximately half of both proteins was in the supernatant fraction after ultracentrifugation (Fig. 3, compare lanes 5 and 6). Both the apo-AAC-TraR fusion protein and the native-length apo-TraR protein expressed from pYCM101 accumulated to much higher levels than did the apo-TraR protein expressed from pJZ335 (Fig. 3A, compare lanes 2 and 6). In the presence of OOHL, the TraR and AAC-TraR fusion proteins from pYCM101 were both produced at higher levels than TraR from pJZ335 (Fig. 3A, compare lanes 3 and 4 to 7 and 8), possibly due to differences between the aacC1 promoter of the mutant and the lac promoter of the wild type. Surprisingly, much of the TraR and AAC-TraR proteins were in the soluble fraction (Fig. 3A, lane 6). We also conclude that the AAC-TraR fusion protein somehow protects the coexpressed native TraR protein from proteolysis.
![]() View larger version (34K): [in a new window] |
FIG. 3. (A) Western immunoblot assays to detect TraR and AAC-TraR fusion proteins prepared from strains KYC55(pJZ372)(pYCM101) and KYC55(pJZ372)(pJZ335) cultured in the presence or absence of 250 nM OOHL. Lanes 1, 3, 5, and 7 represent samples from total lysates, while lanes 2, 4, 6, and 8 represent samples from soluble fractions after ultracentrifugation. (B) ß-Galactosidase specific activities of KYC55(pJZ372)(pYCM107) and its parent strain cultured in the presence or absence of OOHL. The numbers in parentheses represent standard deviations. (C) Western immunoblot assays to detect putative AAC-TraR fusion proteins in the soluble fractions produced from KYC55(pJZ372)(pYCM107) cells cultured in the presence or absence of 250 nM OOHL.
|
To measure the stabilities of the apo-TraR and apo-AAC-TraR fusion proteins produced from pYCM101, we immunoprecipitated these proteins at various time intervals after pulse-labeling them with radiolabeled methionine. We cultured strains containing either pYCM101 or pJZ335 in AT minimal medium in the absence of OOHL. Both the apo-AAC-TraR fusion protein and the cotranslated apo-TraR produced from pYCM101 had a much longer half-life (16 and 12 min, respectively; Fig. 4) than that of apo-TraR produced from pJZ335 (2 min).
![]() View larger version (38K): [in a new window] |
FIG. 4. (A) Pulse-chase experiment to compare the protein stabilities of AAC-TraR fusion protein and the cotranslated TraR produced from KYC55(pJZ372)(pYCM101) to that of TraR produced from KYC55(pJZ372)(pJZ335) in the absence of OOHL. Arrows point to the immunoprecipitated apo-TraR and apo-AAC-TraR fusion protein that had been radiolabeled with [35S]methionine and then treated with excess unlabeled methionine for the time intervals indicated above each lane. (B) Half-lives of TraR and AAC-TraR shown in panel A were quantitated with a Storm PhosphorImager.
|
We identified six new alleles of traR with elevated activities (Table 2). Two of these contain fragments of the E. coli ahpC gene, which encodes an alkyl hydroperoxide reductase subunit C subunit. These two fusions had identical amounts of the aphC gene (19 codons) but differing amounts of upstream DNA. Of the remaining four fusions, one is from the ascF gene, encoding phosphotransferase system enzyme IIBC. Another is from a gene designated b2430, which encodes a putative beta-lactamase. Another is from an ilvC gene, which encodes a ketol-acid reductoisomerase. The last fusion is from the yafO gene, which encodes a hypothetical protein. We did not find significant similarities in size or primary amino acid sequence among these candidates, although all of them have high isoelectric points (between 9 and 10; Table 2).
|
View this table: [in a new window] |
TABLE 2. Results of random fusion screeninga
|
(pE3A7) cultured in the absence of OOHL. This lysate detectably (though weakly) shifted the tra box-containing fragment (Fig. 5C), while cleared lysates from DH5
(pJZ335) did not do so when cultured in the absence of OOHL (Fig. 5C). As expected, when DH5
(pE3A7) or DH5
(pJZ335) (Fig. 5C) was cultured in the presence of OOHL the resulting lysates efficiently shifted the tra box-containing fragment.
![]() View larger version (48K): [in a new window] |
FIG. 5. (A) SDS-PAGE of putative AhpC-TraR fusion proteins overproduced in DH5 in the presence or absence of OOHL. The diagonal arrow indicates the AhpC-TraR proteins produced in the soluble fraction in the absence of OOHL. (B) Immunodetection of TraR proteins, comparing the accumulation of AhpC-TraR and that of wild-type TraR in KYC55(pJZ372) strains containing either pE3A7 or pJZ335 in the presence or absence of OOHL. (C) Gel mobility shift assays of native and AhpC-TraR, using cleared lysates (0.25, 0.5, or 1 µl of extract per lane) made from strains cultured in the absence or presence of OOHL, as indicated.
|
|
|
|---|
For ligand-dependent transcription factors, the isolation of ligand-independent mutants is a commonly applied method to look for residues required for ligand binding or signal transduction. Our selection for constitutive mutants yielded only fusion proteins, despite the fact that such mutants should arise far less frequently than point mutants. This selection strategy was validated using another protein (OccR) (1). We conclude that it may be impossible to find point mutations in traR that lead to a constitutive phenotype.
As described above, the only mutants we obtained from the original selection were cointegrates of two of the plasmids in the parent strain. Additional N-terminal fusions were later obtained by creating a library of such fusions and selecting for OOHL-independent TraR activity. Though the fusion proteins had partially constitutive activity, activity was further enhanced by OOHL. Strikingly, these N-terminal fusions almost completely blocked the rapid proteolysis that characterizes the wild-type apo-TraR. We have argued in the past the OOHL somehow acts as a scaffold for TraR folding (42, 43), and it now appears that certain N-terminal fusions can suppress the need for this scaffold. However, not every N-terminal TraR fusion protein has constitutive activity, inasmuch as we previously described a maltose-binding protein (MBP)-TraR fusion that is fully soluble and stable in vivo in the absence of OOHL but which is transcriptionally inactive (43).
We have speculated in the past that the sole function of OOHL might conceivably be to block TraR proteolysis. The fusion proteins isolated in the present study were far more abundant and protease resistant than wild-type protein and were partially constitutive, supporting this hypothesis. However, OOHL strongly enhanced the activity of these fusion proteins, while having only a modest effect on their abundance or solubility. This suggests that OOHL plays roles in TraR activity that go beyond its proteolytic stability. Similarly, in previous studies we described an MBP-TraR fusion that is proteolytically stable and abundant in the absence of OOHL, but is inactive. This finding also suggests that OOHL does more than simply block TraR proteolysis. We propose that maturation of TraR may occur in at least two sequential steps. According to this idea, TraR can first fold into a form that is soluble and protease resistant, but still not competent for transcriptional activation. An additional step appears to be required to convert TraR to a form that is competent for transcription. If this model is correct, then OOHL appears able to facilitate both maturation steps rapidly, while the fusions described in this study carry out the first step fully but only partially carry out the second step. The MBP-TraR fusion also carries out the first step but is unable to further mature into a transcription-competent form without OOHL.
The dimer form of TraR is the active form for transcriptional activation, and purified apo-TraR is a monomer (43). We were also very interested to know what is the active form of fusion proteins and whether the N-terminal fusions promote dimerization of the fusion proteins (43). Based on the results of gel shift assays (Fig. 5C), we think that the active form of the AhpC-TraR fusion protein is a dimer, and this could also be true for other fusion proteins. While we believe that these N-terminal fusions stabilize TraR and may mildly promote dimerization, OOHL still has a dramatic effect on the dimerization of the fusion proteins, as was shown for AhpC-TraR fusions (Fig. 5C).
Other interesting results from this work are that the apo-ACC-TraR fusion proteins appeared to protect the native apo-TraR protein when both were coexpressed (Fig. 3A, lanes 5 and 6) and that both may contribute to transcriptional activation (compare Fig. 2A and Fig. 3B). Though the reasons for this are unclear, one hypothesis is that monomers of the fusion protein may help protect apo-TraR from misfolding and proteolysis, possibly by forming heterodimers or multimers.
TraR has a hydrophobic core, which in the presence of OOHL is buried inside, where it makes extensive contact with OOHL. In the absence of OOHL, at least some of this hydrophobic core could be exposed to solvent and apo-TraR could thus be vulnerable to aggregation and cytoplasmic proteolysis (43). Its seems possible that the N-terminal portions of the fusion proteins described here might interact with the vulnerable hydrophobic core in some way or mimic the role of OOHL as a folding scaffold and lead the TraR portion of the fusion to fold into a conformation that is not only more soluble and resistant to proteolysis but also transcriptionally active. All foreign fragments in these fusion proteins showed high isoelectric points and are therefore positively charged in vivo. The positive charge of fragments could also lead to enhanced solubility.
The N-terminal fusions described in this study, in addition to the MBP-TraR fusion previously described, can be thought of as protein solubility enhancers, which are a class of proteins that when fused with other proteins normally prone to aggregation, increase the solubility of the fusion proteins. Examples such as MBP and the E. coli glutathione S-transferase have been used for this purpose in many studies (9, 17).
The first two fusion proteins described in this study contained residues 1 to 192 or 1 to 65 of the AAC protein.
The structure of this protein has been resolved by X-ray crystallography (37). To try to understand why fusions to this protein can increase the stability of apo-TraR and cause constitutive activity, we used BLAST to search for proteins similar in sequence to the N-terminal domain of the AAC protein. We found an almost perfect match between the N-terminal residues of AAC and DHFR of S. enterica (Fig. 2C). Interestingly, it was recently proposed that a closely related E. coli DHFR contains an intramolecular chaperone-like sequence at its N terminus (12, 22, 24). Intramolecular chaperones are generally divided into two families: one family in which the chaperone region is proteolytically cleaved after the formation of the mature protein and the other family in which the chaperone region is not cleaved. Examples of the first group are the subtilisin from Bacillus subtilis and the
-lytic protease of Lysobacter enzymogenes (19), while an example of the second group is the DHFR of E. coli (29). It has been proposed that such fragments may exist in many proteins, though it is difficult to predict how many proteins have such sequences. The N-terminal fragment of DHFR acts as both an integral part of the catalytic core and also as an intramolecular chaperone (12, 22). The role of the N terminus of DHFR as a folding chaperone was tested in trans in protein fragment complementation studies (23, 24). Although few studies have been reported on the folding of AAC, we speculate that the N terminus of AAC might function as an intramolecular chaperone, allowing folding of TraR into a conformation that is more resistant to proteolysis. Other TraR fusion proteins such as AhpC-TraR may have similar properties. Although we did not see any significant pattern in the size and sequence similarity of the fused fragments, all had high isoelectric points, similar to other intramolecular chaperone-like sequences (19, 38).
This work was supported by NIH grant GM42893.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»